Ana Marquez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2353166/publications.pdf

Version: 2024-02-01

36 papers	765 citations	567281 15 h-index	552781 26 g-index
37 all docs	37 docs citations	37 times ranked	1596 citing authors

#	Article	IF	Citations
1	Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. Genome Medicine, 2018, 10, 97.	8.2	73
2	A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 286-294.	0.9	58
3	Novel Association of the Interleukin 2â€“Interleukin 21 Region With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2009, 104, 1968-1975.	0.4	51
4	Specific association of a CLEC16A/KIAA0350 polymorphism with NOD2/CARD15â˜ Crohn's disease patients. European Journal of Human Genetics, 2009, 17, 1304-1308.	2.8	50
5	Role of the PXR gene locus in inflammatory bowel diseases. Inflammatory Bowel Diseases, 2007, 13, 1484-1487.	1.9	48
6	Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis. Human Molecular Genetics, 2018, 27, 4333-4343.	2.9	42
7	IL23R and IL12B polymorphisms in spanish IBD patients: No evidence of interaction. Inflammatory Bowel Diseases, 2008, 14, 1192-1196.	1.9	38
8	Polymorphisms in the selenoprotein S gene: lack of association with autoimmune inflammatory diseases. BMC Genomics, 2008, 9, 329.	2.8	35
9	Brief Report: Association of HLAâ€“DRB1*01 With IgA Vasculitis (Henochâ€šÃ¶nlein). Arthritis and Rheumatology, 2015, 67, 823-827.	5.6	35
10	Association of HLA-B*41:02 with Henoch-SchÃ¶nlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Research and Therapy, 2015, 17, 102.	3.5	33
11	Confirmation of â˜174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenetics and Genomics, 2014, 24, 1-5.	1.5	32
12	Lack of validation of genetic variants associated with antiâ€“tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Research and Therapy, 2014, 16, R66.	3.5	25
13	Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: A Study in the Spanish population and a meta-analysis. Inflammatory Bowel Diseases, 2009, 15, 1697-1704.	1.9	21
14	Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids. Annals of the Rheumatic Diseases, 2022, 81, 1290-1300.	0.9	20
15	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. PLoS ONE, 2019, 14, e0213073.	2.5	19
16	Association of theFCGR3A-158F/V Gene Polymorphism with the Response to Rituximab Treatment in Spanish Systemic Autoimmune Disease Patients. DNA and Cell Biology, 2012, 31, 1671-1677.	1.9	18
17	New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. Journal of Medical Genetics, 2017, 54, 38-46.	3.2	18
18	A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohnâ€™s disease. Scientific Reports, 2020, 10, 1862.	3.3	18

#	Article	IF	Citations
19	Association Between â˜'174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases. DNA and Cell Biology, 2012, 31, 1486-1491.	1.9	17
20	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	2.5	17
21	IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Molecular Biology Reports, 2013, 40, 4851-4856.	2.3	15
22	Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition. BMC Medical Genetics, 2013, 14, 52.	2.1	12
23	Emerging aspects of molecular biomarkers for diagnosis, prognosis and treatment response in rheumatoid arthritis. Expert Review of Molecular Diagnostics, 2016, 16, 663-675.	3.1	12
24	Rheumatoid arthritis response to treatment across IgG1 allotype â€“ anti-TNF incompatibility: a case-only study. Arthritis Research and Therapy, 2015, 17, 63.	3.5	9
25	Leveraging Genetic Findings for Precision Medicine in Vasculitis. Frontiers in Immunology, 2019, 10, 1796.	4.8	7
26	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. Rheumatology, 2022, 61, 1204-1210.	1.9	7
27	Specific association ofIL17Agenetic variants with panuveitis. British Journal of Ophthalmology, 2015, 99, 566-570.	3.9	6
28	Approaching Shared Pathophysiology in Immune-Mediated Diseases through Functional Genomics. Genes, 2020, 11, 1482.	2.4	6
29	No Evidence of Association between Common Autoimmunity STAT4 and IL23R Risk Polymorphisms and Non-Anterior Uveitis. PLoS ONE, 2013, 8, e72892.	2.5	4
30	Strong Protective Effect of DR3 Against Ulcerative Colitis in the Spanish Population. American Journal of Gastroenterology, 2007, 102, 2762-2766.	0.4	3
31	Two Functional Variants of IRF5 Influence the Development of Macular Edema in Patients with Non-Anterior Uveitis. PLoS ONE, 2013, 8, e76777.	2.5	3
32	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PLoS ONE, 2018, 13, e0209343.	2.5	3
33	Genetic overlap between type 1 diabetes and other autoimmune diseases. Seminars in Immunopathology, 2022, 44, 81-97.	6.1	3
34	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. Scientific Reports, 2021, 11, 16163.	3.3	1
35	Analysis of two autoimmunity genes, IRAK1 and MECP2, in giant cell arteritis. Clinical and Experimental Rheumatology, 2014, 32, S30-3.	0.8	1
36	LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 208-209.	0.8	0